• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings.

    "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage."

    "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our commercial growth."

    As Managing Director of BioGenerator Ventures, Winkeler led investments, sat on portfolio company boards of directors, and built new companies. She managed investments including Panome Bio, a private-equity-backed multi-omics startup, RevivBio, leveraging protein engineering and advanced microfluidics for applications in agriculture and other industries, and Pairidex, using novel droplet digital PCR technology to improve cancer outcomes.

    "Crystal possesses a rare combination of scientific depth with the ability to build meaningful business relationships," said Edward Weinstein, CEO of Panome Bio. "Her talents have been instrumental to the success of multiple startups."

    Prior to BioGenerator Ventures, Winkeler was Chief Operating Officer and Vice President of R&D of Canopy Biosciences, acquired by Bruker (NASDAQ:BRKR), where it now operates as Bruker Spatial Biology. Winkeler co-founded Canopy Biosciences and was instrumental in the growth of the company, including multiple PE-backed acquisitions. She led efforts in fundraising, technology sourcing and licensing, commercialization, operations, and business development. At the time that she left Bruker, Winkeler led an international team of over 40 people across sites in St. Louis, Leipzig and Hannover in Germany, and the Bay Area.

    "As Canopy's Board Chairman, I witnessed Crystal's leadership of the Canopy team through critical product launches and business development milestones," said Frank Witney, Operating Partner at Ampersand Capital Partners.

    Prior to Canopy, Winkeler spent four years at BioGenerator Ventures where she led due diligence for seed investments in companies such as Benson Hill, CoverCress, and Confluence Life Sciences.

    Winkeler completed a Ph.D. in Molecular Cell Biology at Washington University.

    Solis has demonstrated significant traction across start-ups to large multinational agriculture companies, recruited and grown a team of industry-experienced scientists, and launched product offerings in plant transformation and gene editing. The company expanded its management team, secured a license to the Pairwise Fulcrum™ Platform, entered the whole-genome-sequencing space through the acquisition of Ferris Genomics, secured new investment from Cultivation Capital, and dramatically increased sales.

    Solis' major investors are Hermann Companies, Cultivation Capital, Jim McKelvey's Saloniki Investments, BioGenerator Ventures, and QRM Capital. Additional investors include St. Louis Arch Angels, Missouri Technology Corporation, Helix Fund, CIG Spectrum, Hypha Life Sciences, and various angel investors.

    About Solis Agrosciences

    Solis Agrosciences is the trusted partner for high-quality AgTech research services. We generate gene-edited and transgenic crops, plant phenotype and efficacy data, end-to-end genomics sequencing services, and individually tailored research solutions for our startup and corporate customers. Solis' highly trained and industry-experienced scientists operate in the 39 North AgTech Innovation District of St. Louis, Missouri. Visit solisagrosciences.com to learn more.

    About Cultivation Capital

    Cultivation Capital is an early-stage venture capital firm investing in software technology, life sciences, agriculture technology, and geospatial technology companies. Since its founding in 2012, the firm has invested in over 150 companies and is recognized as one of the most active early-stage investors in the United States. For more information, visit cultivationcapital.com

    About Hermann Companies

    Founded in 1956, Hermann Companies combines three generations of experience to make investments across a spectrum of asset classes and industries. Hermann offers a variety of capital solutions to accomplish its goal of partnering with strong, entrepreneurial teams through meaningful direct investments. Visit hermcos.com to learn more.

    39 North AgTech Innovation District, St. Louis, Missouri is a vibrant innovation district cultivating the infrastructure, talent, and access to capital to facilitate agrifood tech innovation and to advance ideas from lab to market. Visit 39northstl.org to learn more.

    CONTACT

    [email protected]



    Primary Logo

    Get the next $BRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands

      Bruker Corporation (NASDAQ:BRKR) today announced the shipment and installation of the 15th InSight WLI 3D optical metrology system to a leading semiconductor manufacturer. The installation is part of a larger order from this semiconductor manufacturer for 27 Bruker optical metrology systems in 2025. This reflects the growing demand for high-performance metrology that can support advanced packaging requirements in the latest generation AI high-performance chip manufacturing processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624897472/en/Bruker InSight WLI 3D optical metrology systems measure key manufacturing process st

      6/24/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

      Bruker strengthens its applied markets leadership with RECIPE majority investment and unveils timsMetabo™, a next-generation platform for high-sensitivity small molecule analysis Bruker Corporation (NASDAQ:BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. This press release features multimedia. View the full re

      6/3/25 11:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

      Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research services Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603323690/en/biocrates kits and pipettes biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits co

      6/3/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      6/9/25 4:15:11 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Francis Laura was granted 4,498 shares (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      5/19/25 5:08:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Ornell John A exercised 5,000 shares at a strike of $18.15, increasing direct ownership by 19% to 31,445 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      5/14/25 4:12:44 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bruker downgraded by Citigroup with a new price target

      Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00

      5/22/25 8:18:13 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on Bruker with a new price target

      Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

      12/19/24 7:30:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • UBS initiated coverage on Bruker with a new price target

      UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

      12/10/24 8:26:42 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials